NewsSource: EClinCloud

Event Preview | Meet EClinCloud at the China Forum on Skin Diseases and Transdermal Drug Delivery Research and Development

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration


On November 19, 2023, the China Forum on Skin Diseases and Transdermal Drug Delivery Research and Development, themed "Technology-Empowered, Illuminating Medical Research," will be held at the Beijing Renwei Hotel. Discussions will focus in depth on clinical research topics in skin diseases—such as alopecia, psoriasis, and atopic dermatitis—and transdermal drug delivery.


The forum will bring together experts from research universities and institutes, prominent clinical investigators, leading investment firms, top pharmaceutical R&D companies, and innovative technology platforms to discuss project initiation, study design, regulatory policy, clinical design, clinical execution, translational medicine, and commercialization for skin diseases and transdermal drug delivery, exploring the competitive landscape and how to break through in the future.


Date

November 19, 2023

Location

Conference Room 801, 8th Floor, Beijing Renwei Hotel
19 Panjiayuan Nanli, Chaoyang District, Beijing


Dr. Qin Long, Founder and CEO of EClinCloud, has been invited to attend and will deliver a keynote presentation titled "Electronic Collection of Endpoint Assessment Data in Dermatology", as well as participate in a panel discussion on future-oriented scientific strategies for topical drugs.

EClinCloud's clinical endpoint assessment solutions span various therapeutic areas, and the company has also accumulated extensive experience in scale copyright management and electronic scale data collection in dermatology.


Article illustration

Dr. Qin Long

EClinCloud | Founder & CEO


  • Over 17 years of experience in technology applications for the clinical research industry;

  • An innovative and inspiring leader, and a pioneer in promoting and implementing eCOA, EDC, CTMS, and other technology solutions in clinical trial research in China;

  • Previously served as Asia-Pacific head at several international technology companies, leading rapid regional business growth;

  • An entrepreneur driven by academia and science, passionately dedicated to shaping new models for future clinical trials.

Note

✦

To register for the conference, please follow the "Guoxin Pharmaceutical Technology (国信医药科技)" WeChat Official Account

Get the Full Conference Agenda






About EClinCloud

EClinCloud is a technology company focused on clinical R&D, offering an integrated, interconnected all-in-one cloud platform for clinical trials (including solutions across technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, covering scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, etc.). By combining cutting-edge technology with life data, EClinCloud builds a globally leading, "patient-centric" clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.







Article illustration

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.